Nationales Centrum für Tumorerkrankungen (NCT)
Research facility
Location:
Heidelberg, Dresden, Berlin, Essen, Köln, Würzburg, Erlangen, Regensburg, Augsburg, Tübingen, Stuttgart, Ulm,
Germany (DE)
ISNI: 0000000088550365
ROR: https://ror.org/01txwsw02
Clinical outcome of personalised treatment guided by genome and transcriptome sequencing in patients with neuroendocrine neoplasms: Updated results from the German NCT/DKTK MASTER trial (2019)
Kreutzfeldt S, Apostolidis L, Oles M, Horak P, Heilig CE, Heining C, Hutter B, et al.
Conference contribution
Chemotherapy (CT)-induced anaemia in patients (pts) treated with dose-dense regimen: Results of the prospectively randomised anaemia substudy from the neoadjuvant GeparOcto study (2019)
Tesch H, Loibl S, Kast K, Jackisch C, Moebus V, Buchen S, Untch M, et al.
Conference contribution
Impact of chemotherapy-induced ovarian failure (CIOF) on disease-free survival (DFS) and overall survival (OS) in young women with early breast cancer (EBC) (2019)
Furlanetto J, Nekljudova V, Schneeweiss A, Thode C, Denkert C, Untch M, Bassy M, et al.
Conference contribution
Risk factors for locoregional recurrence (LRR) after neoadjuvant chemotherapy: Pooled analysis of prospective neoadjuvant breast cancer (BC) trials (2019)
Werutsky G, Untch M, Hanusch C, Fasching P, Blohmer JU, Seiler S, Denkert C, et al.
Conference contribution
Utility of the CPS plus EG scoring system in triple-negative breast cancer treated with neoadjuvant chemotherapy (2019)
Marme F, Solbach C, Michel L, Fasching P, Schneeweiss A, Blohmer JU, Rezai M, et al.
Conference contribution
Nab-paclitaxel improves disease-free survival in early breast cancer: GBG 69–Geparsepto (2019)
Untch M, Jackisch C, Schneeweiss A, Schmatloch S, Aktas B, Denkert C, Schem C, et al.
Journal article
Intratumoral RNA-based TLR-7/-8 and RIG-I agonist CV8102 alone and in combination with anti-PD-1 in a Phase I dose-escalation and expansion trial in patients with advanced solid tumors (2019)
Eigentler T, Krauss J, Schreiber J, Weishaupt C, Terheyden P, Heinzerling L, Mohr P, et al.
Conference contribution
Clinical relevance of comprehensive genomic analysis in patients with advanced-stage neuroendocrine neoplasms: Results from the MASTER trial of the German Cancer Consortium (2019)
Kreutzfeldt S, Apostolidis L, Oles M, Horak P, Heilig CE, Heining C, Hutter B, et al.
Conference contribution
Influence of PIK3CA mutations on breast cancer proliferation, lymphocyte infiltration and clinical outcome: Pooled analysis of 484 patients from three prospective multicentre GBG trials (2019)
Jank P, Loibl S, Fasching P, Karn T, Marme F, Mueller V, Schem C, et al.
Conference contribution
SMARCA4 loss is synthetic lethal with CDK4/6 inhibition in non-small cell lung cancer (2019)
Xue Y, Meehan B, Fu Z, Wang XQD, Fiset PO, Rieker R, Levins C, et al.
Journal article